NAD+ (nicotinamide adenine dinucleotide) is not a peptide. It's a coenzyme — a small molecule that enzymes need to function. But it sits at the center of aging biology research because it connects three of the most studied hallmarks of aging: mitochondrial dysfunction, DNA damage accumulation, and epigenetic changes.

Every cell in the body uses NAD+ for two fundamentally different purposes. First, it's an electron carrier in the metabolic reactions that convert food into energy (ATP). This is the textbook function — NAD+ shuttles electrons in the citric acid cycle and oxidative phosphorylation. Second, it's consumed as a substrate by enzymes that repair DNA, regulate gene expression, and maintain cellular health. These enzymes literally break NAD+ apart to do their jobs.¹

This dual role creates a metabolic tension: the same molecule needed for energy production is also needed for cellular maintenance. When NAD+ levels are abundant, cells can do both. When levels decline — as they do with age — cells face a tradeoff. The research question driving the NAD+ field is whether restoring NAD+ levels in aged tissues can resolve this tradeoff and reverse age-related functional decline.

Multiple studies have documented that NAD+ levels decrease with age across tissue types and across species. In humans, studies measuring NAD+ in skin, blood, liver, and brain tissue have consistently shown lower levels in older individuals compared to younger ones. The decline is not subtle — some studies report 50% reductions in tissue NAD+ between young adulthood and old age.²

The mechanisms driving this decline are multifaceted. CD38 — an enzyme that degrades NAD+ — increases in expression with age, particularly in inflammatory contexts. PARP enzymes, which consume NAD+ during DNA repair, become more active as DNA damage accumulates with age. And the enzymes that synthesize NAD+ (NAMPT in the salvage pathway) decrease in activity. The result is a supply-and-demand imbalance: NAD+ is being consumed faster and produced slower.

This decline is correlated with — but not proven to cause — many features of aging: reduced mitochondrial function, accumulated DNA damage, epigenetic drift, stem cell exhaustion, and immune system deterioration. A central question in the field is the direction of causality: does NAD+ decline drive aging, or does aging drive NAD+ decline? The answer appears to be both — a vicious cycle where each accelerates the other.³

The sirtuin family (SIRT1-7) is a group of enzymes that depend absolutely on NAD+ — they cannot function without it. Sirtuins have been called "longevity genes" because overexpression of certain sirtuins extends lifespan in yeast, worms, flies, and mice. They regulate:

• Gene expression (SIRT1, SIRT6, SIRT7 — histone deacetylation)
• Mitochondrial function (SIRT3, SIRT4, SIRT5 — mitochondrial deacetylation)
• DNA repair (SIRT1, SIRT6 — chromatin remodeling at damage sites)
• Inflammation (SIRT1 — NF-κB deacetylation)
• Metabolism (SIRT1 — PGC-1α activation, SIRT3 — fatty acid oxidation)

As NAD+ declines with age, sirtuin activity decreases proportionally. This creates a cascade: reduced SIRT1 activity means less gene regulation, reduced SIRT3 activity means less efficient mitochondria, and reduced SIRT6 activity means impaired DNA repair.⁴

The landmark 2013 study by Gomes et al. in Cell demonstrated this connection directly. They showed that declining NAD+ levels in aged mice caused a specific breakdown in nuclear-mitochondrial communication mediated by SIRT1, and that restoring NAD+ levels with the precursor NMN reversed this communication breakdown and restored mitochondrial function in muscle tissue to levels comparable to young mice.⁵

PARP enzymes (poly-ADP-ribose polymerases) are the other major consumers of cellular NAD+. When DNA is damaged — by oxidative stress, radiation, or metabolic byproducts — PARP enzymes are recruited to the damage site, where they use NAD+ to build polymer scaffolds that recruit repair machinery.

DNA damage increases with age. More damage means more PARP activation, which means more NAD+ consumption. In severely damaged cells, PARP can consume so much NAD+ that there's not enough left for sirtuin activity — creating a competition between DNA repair and gene regulation for a limited NAD+ pool.⁶

Research by Fang et al. demonstrated this competition in models of accelerated aging. In animal models of ataxia-telangiectasia (a condition of defective DNA repair), NAD+ supplementation improved DNA repair capacity, restored mitochondrial function, and extended healthy lifespan. Similar results were seen in models of Werner syndrome (another premature aging condition), where NAD+ supplementation via NMN improved multiple aging parameters.⁷

NAD+ is essential for mitochondrial energy production — it carries electrons through Complexes I through IV of the electron transport chain. When NAD+ levels fall, electron transport chain efficiency decreases, ATP production drops, and reactive oxygen species (ROS) production increases.

The mitochondrial research has shown that NAD+ supplementation in aged mice restores:

• Mitochondrial membrane potential (the electrical gradient that drives ATP synthesis)
• Respiratory chain complex activity (the efficiency of each step in electron transport)
• Oxidative phosphorylation capacity (total ATP output)
• Mitochondrial biogenesis (the creation of new mitochondria through PGC-1α/SIRT1 signaling)

A key study by Zhang et al. in Science (2016) showed that NAD+ repletion improved mitochondrial function in aged mice and enhanced adult stem cell function, resulting in improved muscle regeneration capacity and extended lifespan.⁸

A significant research question is whether it's better to supplement NAD+ directly or to supplement its precursors — NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Each has a different position in the NAD+ synthesis pathway:

• NR → NMN → NAD+ (the salvage pathway)
• NR is converted to NMN by NRK enzymes
• NMN is converted to NAD+ by NMNAT enzymes

Most published aging studies have used NMN or NR rather than NAD+ directly, primarily because these precursors are orally bioavailable in animal models while NAD+ itself is a larger molecule with less established oral absorption.

The relative efficacy of direct NAD+ supplementation versus precursor supplementation is an active area of investigation. Some researchers argue that direct NAD+ avoids potential bottlenecks in the conversion enzymes. Others argue that precursors are more efficiently absorbed. OSYRIS offers NAD+ in its active form for research protocols that require the coenzyme itself rather than a precursor.⁹

NAD+ depletion has been implicated in several models of neurodegenerative disease. Brain tissue is particularly vulnerable to NAD+ decline because neurons have high metabolic demands and limited regenerative capacity.

Research in mouse models of Alzheimer's disease showed that NMN supplementation (raising NAD+ levels) reduced amyloid-beta accumulation, decreased neuroinflammation, improved synaptic plasticity, and enhanced cognitive performance on behavioral tests. Similar findings have been reported in Parkinson's disease and age-related cognitive decline models.¹⁰

The neurological research connects NAD+ to multiple neuroprotective mechanisms: SIRT1-mediated gene regulation in neurons, SIRT3-mediated mitochondrial protection, PARP-mediated DNA repair in post-mitotic cells, and NAD+-dependent calcium signaling.

Human evidence is limited. The most dramatic NAD+ results come from mouse studies. Human clinical trials of NMN and NR have shown that these precursors can raise blood NAD+ levels, but clinically meaningful health outcomes in humans have not been conclusively demonstrated.

Mouse models are not humans. Mice live ~2 years and have different metabolic rates, body compositions, and aging trajectories. Lifespan extension in mice does not guarantee lifespan extension in humans.

Causality vs. correlation. While NAD+ decline correlates with aging, proving that NAD+ decline causes specific aging phenotypes (vs. being a consequence of other aging processes) requires more investigation.

Optimal dosing and timing. Whether NAD+ supplementation is most beneficial as a preventive measure (starting young) or a restorative measure (starting in old age) is unknown.

Commercial hype vs. science. The NAD+ field has attracted significant commercial interest, which has sometimes outpaced the evidence. The research is genuinely promising, but the gap between mouse studies and human health claims should be clearly acknowledged.